The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?

[1]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[2]  S. Travis,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety , 2011, The American Journal of Gastroenterology.

[3]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[4]  P. Rutgeerts,et al.  Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  S. Hanauer,et al.  Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  J. Schölmerich,et al.  Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data , 2010, The American Journal of Gastroenterology.

[7]  P. Rutgeerts,et al.  Role of genetics in prediction of disease course and response to therapy. , 2010, World journal of gastroenterology.

[8]  W. Dixon,et al.  Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register , 2010, Arthritis care & research.

[9]  D. Hommes,et al.  847t Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis , 2010 .

[10]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[11]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[12]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[13]  P. Rutgeerts,et al.  The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies , 2010, Alimentary pharmacology & therapeutics.

[14]  P. Munkholm,et al.  Overall and cause‐specific mortality in Crohn's disease: A meta‐analysis of population‐based studies , 2009, Inflammatory bowel diseases.

[15]  Dawn B. Beaulieu,et al.  Durability of infliximab in Crohn's disease: A single‐center experience , 2009, Inflammatory bowel diseases.

[16]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[17]  S. Hanauer,et al.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.

[18]  Andre Franke,et al.  Genetic risk profiling and prediction of disease course in Crohn's disease patients. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[20]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[21]  S. Travis,et al.  Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review , 2009, Inflammatory bowel diseases.

[22]  W. Sandborn,et al.  Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials , 2009, Alimentary pharmacology & therapeutics.

[23]  M. Vos,et al.  961 Infliximab Discontinuation in Crohn's Disease Patients in Stable Remission On Combined Therapy with Immunosuppressors: A Prospective Ongoing Cohort Study , 2009 .

[24]  D. Rubin,et al.  W1093 Predictors and Timing of Adalimumab (ADA) Dose Escalation in Patients with Crohn's Disease (CD) , 2009 .

[25]  C. Lacroix,et al.  Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. , 2009, Archives of neurology.

[26]  A. Katalinic,et al.  P183 - Predictive factors for a mild course of Crohn's disease , 2009 .

[27]  M. Regueiro,et al.  Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.

[28]  A. Bitton,et al.  Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double‐blind, placebo‐controlled pilot study , 2009, Inflammatory bowel diseases.

[29]  E. Benchimol,et al.  Budesonide for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[30]  Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy ? , 2009 .

[31]  Jonathan Cohen.  Optical contrast endoscopy: is it ready for routine use? , 2009, Gastroenterology.

[32]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[33]  G. Savoye,et al.  Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn’s Disease , 2009, Digestive Diseases and Sciences.

[34]  P. Rutgeerts,et al.  Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. , 2008, Gastroenterology.

[35]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[36]  W. Reinisch,et al.  Adalimumab Effectiveness in TNF-Antagonist-Naïve Patients and in Infliximab Nonresponders with Crohnʼs Disease: Results from the Care Study , 2008 .

[37]  M. Turner,et al.  Safety of Infliximab and Other Crohnʼs Disease Therapies: Treat™ Registry Data with 24,575 Patient-Years of Follow-up , 2008 .

[38]  K. Van Steen,et al.  Long-term outcome after infliximab for refractory ulcerative colitis. , 2008, Journal of Crohn's & colitis.

[39]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[40]  L. Peyrin-Biroulet,et al.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  G. D'Haens,et al.  920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial , 2008 .

[42]  P. Rutgeerts,et al.  M1143 Benefits of Dosage Adjustment with Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial , 2008 .

[43]  J. Mary,et al.  921 Long Term Follow-Up of a Cohort of Steroid-Dependent Crohn's Disease Patients Included in a Randomized Trial Evaluating Short Term Infliximab Combined with Azathioprine , 2008 .

[44]  P. Rutgeerts,et al.  494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study , 2008 .

[45]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[46]  Matthias Schneider,et al.  Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? , 2008, Arthritis and rheumatism.

[47]  W. Bemelman,et al.  European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .

[48]  B F Warren,et al.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. , 2008, Journal of Crohn's & colitis.

[49]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[50]  J. Belaiche,et al.  Predictors of severe Crohn's disease , 2008, Scandinavian journal of gastroenterology.

[51]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[52]  G. Lichtenstein.  New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2008 .

[53]  A. Griffiths,et al.  Budesonide for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.

[54]  S. Rudolph,et al.  Long-Term Durability of Crohn’s Disease Treatment with Infliximab , 2008, Digestive Diseases and Sciences.

[55]  M. Regueiro,et al.  Infliximab dose intensification in Crohn's disease , 2007, Inflammatory bowel diseases.

[56]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[57]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[58]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[59]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[60]  K. Van Steen,et al.  New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2007, Gut.

[61]  S. Schreiber,et al.  P178 Early Crohn's Disease Shows High Levels of Remission to Therapy with Adalimumab: Sub-Analysis of Charm , 2007 .

[62]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[63]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[64]  Konstantinos H. Katsanos,et al.  Predictors of early response to infliximab in patients with ulcerative colitis , 2007, Inflammatory bowel diseases.

[65]  S. Hanauer,et al.  European evidence-based consensus on the diagnosis and management of Crohn’s disease , 2007, Gut.

[66]  O. Dewit,et al.  Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. , 2007, Acta gastro-enterologica Belgica.

[67]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[68]  A. Zinsmeister,et al.  A population‐based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis , 2006, Inflammatory bowel diseases.

[69]  D. Jewell,et al.  Fistulating Anal Crohn’s Disease: Results of Combined Surgical and Infliximab Treatment , 2006, Diseases of the colon and rectum.

[70]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[71]  P. Rutgeerts,et al.  Sustained Clinical Remission in Patients with Moderate to Severe Crohnʼs Disease with Adalimumab, Regardless of Anti-TNF History or Concomitant Immunosuppressant Therapy: 1173 , 2006 .

[72]  H. Drummond,et al.  The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohort , 2006, Alimentary pharmacology & therapeutics.

[73]  S. Dorn.  Predictors of Crohn's disease. , 2006, Gastroenterology.

[74]  S. Hanauer,et al.  Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease , 2006, The American Journal of Gastroenterology.

[75]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[76]  M. Bala,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease , 2006 .

[77]  A. Forbes,et al.  European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.

[78]  P. Rutgeerts,et al.  Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.

[79]  J. Sabate,et al.  Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. , 2006, Gastroenterologie clinique et biologique.

[80]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[81]  P. Rutgeerts,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. , 2006, Gastrointestinal endoscopy.

[82]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[83]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[84]  A. Lacy,et al.  Crohn's Disease Patients Carrying Nod2/CARD15 Gene Variants Have an Increased and Early Need for First Surgery due to Stricturing Disease and Higher Rate of Surgical Recurrence , 2005, Annals of surgery.

[85]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[86]  F. Rizzello,et al.  Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[87]  G. Greenberg,et al.  Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials , 2005, The American Journal of Gastroenterology.

[88]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[89]  P. Couzigou,et al.  Predictors of response to infliximab in luminal Crohn's disease. , 2005, Gastroenterologie clinique et biologique.

[90]  S. Targan,et al.  Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab , 2005, The American Journal of Gastroenterology.

[91]  P. Rutgeerts,et al.  Randomized , Placebo-Controlled Trial of Certolizumab Pegol CDP 870 ) for Treatment of Crohn ’ s Disease , 2005 .

[92]  E. Kuipers,et al.  Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study , 2004, Alimentary pharmacology & therapeutics.

[93]  B. Sands,et al.  Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[94]  S. Hanauer,et al.  An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease , 2004, American Journal of Gastroenterology.

[95]  Samir A. Shah,et al.  Smoking and Immunomodulators do not Influence the Response or Duration of Response to Infliximab in Crohn's Disease , 2004, Inflammatory bowel diseases.

[96]  J. Gisbert,et al.  Predictors of response to infliximab in patients with fistulizing Crohn's disease. , 2004, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[97]  J. Genschel,et al.  Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation , 2004, Alimentary pharmacology & therapeutics.

[98]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[99]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[100]  M. Bala,et al.  Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and Surgeries , 2004, American Journal of Gastroenterology.

[101]  W. Reinisch,et al.  Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[102]  J. Satsangi,et al.  An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[103]  R. Panaccione,et al.  Combined Seton Placement, Infliximab Infusion, and Maintenance Immunosuppressives Improve Healing Rate in Fistulizing Anorectal Crohn’s Disease , 2003, Diseases of the colon and rectum.

[104]  R. Kozarek,et al.  Immunomodulators and “On Demand” Therapy with Infliximab in Crohn's Disease: Clinical Experience with 400 Infusions , 2003, American Journal of Gastroenterology.

[105]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[106]  G. Marchal,et al.  Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's Disease , 2003, American Journal of Gastroenterology.

[107]  J. Achkar,et al.  Predictors of response to infliximab in patients with Crohn's disease. , 2002, Gastroenterology.

[108]  J. Belaiche,et al.  Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease , 2002, American Journal of Gastroenterology.

[109]  J. Belaiche,et al.  A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .

[110]  M. Bala,et al.  Infliximab Improves Quality of Life in Patients with Crohn's Disease , 2002, Inflammatory bowel diseases.

[111]  C. Folwaczny,et al.  The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. , 2002, Gastroenterology.

[112]  P. Munkholm,et al.  Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. , 2002, Gastroenterology.

[113]  J. Belaiche,et al.  Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease , 2002, American Journal of Gastroenterology.

[114]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[115]  S. Targan,et al.  Mutations in NOD 2 Are Associated With Fibrostenosing Disease in Patients With Crohn ’ s Disease , 2002 .

[116]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[117]  S. Targan,et al.  ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. , 2001, Gastroenterology.

[118]  W. Sandborn,et al.  Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.

[119]  S. Hanauer,et al.  Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.

[120]  Samir A. Shah,et al.  Clinical experience with infliximab therapy in 100 patients with Crohn's disease , 2000, American Journal of Gastroenterology.

[121]  J. Markowitz,et al.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.

[122]  M. Kamm,et al.  Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.

[123]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[124]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[125]  J. Belaiche,et al.  Clinical pattern of corticosteroid dependent Crohn's disease , 1998, European journal of gastroenterology & hepatology.

[126]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[127]  G. Greenberg,et al.  Oral Budesonide for Active Crohn's Disease , 1994 .

[128]  D. Jewell,et al.  A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.

[129]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[130]  G. Greenberg,et al.  Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. , 1994, The New England journal of medicine.

[131]  P. Munkholm,et al.  Intestinal cancer risk and mortality in patients with Crohn's disease. , 1993, Gastroenterology.

[132]  P. Munkholm,et al.  Colorectal cancer risk and mortality in patients with ulcerative colitis. , 1992, Gastroenterology.

[133]  H. Bryant,et al.  Effect of cigarette smoking on recurrence of Crohn's disease. , 1990, Gastroenterology.

[134]  R. Modigliani,et al.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. , 1990, Gastroenterology.

[135]  B. Pasternack,et al.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.

[136]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.